WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 574978
Description: Falipamil hydrochloride is a calcium channel antagonist potentially for the treatment of ischaemic heart disorder and sinus.
MedKoo Cat#: 574978
Name: Falipamil hydrochloride
Chemical Formula: C24H33ClN2O5
Exact Mass: 464.2078
Molecular Weight: 464.99
Elemental Analysis: C, 61.99; H, 7.15; Cl, 7.62; N, 6.02; O, 17.20
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: AQ-A39 HCl; Falipamil hydrochloride; Falipamil HCl
IUPAC/Chemical Name: 1H-Isoindol-1-one, 2-(3-(((2-(3,4-dimethoxyphenyl)ethyl)methyl)amino)propyl)-2,3-dihydro-5,6-dimethoxy-, monohydrochloride
InChi Key: SSFPIVGEBUWFAZ-UHFFFAOYSA-N
InChi Code: InChI=1S/C24H32N2O5.ClH/c1-28-20-9-8-17(13-21(20)29-2)7-5-10-25-11-6-12-26-16-18-14-22(30-3)23(31-4)15-19(18)24(26)27;/h8-9,13-15,25H,5-7,10-12,16H2,1-4H3;1H
SMILES Code: O=C1N(CCCNCCCC2=CC=C(OC)C(OC)=C2)CC3=C1C=C(OC)C(OC)=C3.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 464.99 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Boucher M, Chassaing C, Chapuy E. Cardiac electrophysiological effects of falipamil in the conscious dog: comparison with alinidine. Eur J Pharmacol. 1996 Jun 13;306(1-3):93-8. PubMed PMID: 8813620.
2: Boucher M, Chassaing C, Chapuy E, Duchêne-Marullaz P. Chronotropic cardiac effects of falipamil in conscious dogs: interactions with the autonomic nervous system and various ionic conductances. J Cardiovasc Pharmacol. 1994 Apr;23(4):569-75. PubMed PMID: 7516006.
3: Ilias W, Lackner F, Zimpfer M. [The intraoperative use of falipamil (AQ-A39), a new calcium antagonist with specific bradytropic properties]. Anaesthesist. 1990 Oct;39(10):487-92. German. PubMed PMID: 2278367.
4: Roth W, Koss FW, Hallinan D, Lambe R, Darragh A. Pharmacokinetics of falipamil after intravenous administration to humans. J Pharm Sci. 1990 May;79(5):415-9. PubMed PMID: 2352161.
5: Naudascher M, Jaillon P, Lecocq B, Lecocq V, Ferry A, Hilaire J, Maria JF. Effects of falipamil (AQ-A 39) on heart rate and blood pressure in resting and exercising healthy volunteers. J Cardiovasc Pharmacol. 1989 Jul;14(1):1-5. PubMed PMID: 2475699.